[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Turner C, Pateman B: A study of district nurses' experiences of continuous ambulatory chemotherapy. Br J Community Nurs; 2000 Aug;5(8):396-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of district nurses' experiences of continuous ambulatory chemotherapy.
  • As a result of technical developments and policies that promote shorter hospital stays, patients are increasingly receiving high technology treatment in the community.
  • The administration of ambulatory intravenous chemotherapy at home is an example of such treatment.
  • Despite being generalist nurses, district nurses (DNs) are involved in what could be viewed as 'specialist' care - advising and supporting patients while they are receiving treatment.
  • This article reports on a study of 20 DNs from one community trust and examines the sources of the knowledge and skills used in caring for these patients and the communication links with the regional cancer centre.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Community Health Nursing. Home Infusion Therapy / nursing. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12271233.001).
  • [ISSN] 1462-4753
  • [Journal-full-title] British journal of community nursing
  • [ISO-abbreviation] Br J Community Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Moodley M, Tunkyi K, Moodley J: Gestational trophoblastic syndrome: an audit of 112 patients. A South African experience. Int J Gynecol Cancer; 2003 Mar-Apr;13(2):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic syndrome: an audit of 112 patients. A South African experience.
  • Gestational trophoblastic disease (GTD) represents a spectrum of histologically distinct entities including molar pregnancy and choriocarcinoma.
  • With the advent of sensitive assays for detection of serum beta human chorionic gonadotrophin (HCG) and ultrasound, GTD can now be detected earlier in pregnancy.
  • Of 112 patients, there were 78 patients (70%) with hydatidiform mole and 34 patients (30%) with choriocarcinoma.
  • Suction curettage was the main treatment modality for patients with molar pregnancy while choriocarcinoma was treated primarily with chemotherapy.
  • A total of 72 percent of patients with molar pregnancy and 28 percent with choriocarcinoma had complete remission after initial treatment.
  • Twelve patients died during the course of treatment mainly due to late presentation and advanced metastatic disease.
  • Age, parity, previous history, initial uterine size, presence of theca-lutein cysts, and initial betaHCG concentration was not found to be prognostic for persistent trophoblastic disease.
  • Similar to other studies, the majority of patients with molar pregnancy were treated with suction curettage while the majority of patients with choriocarcinoma were treated with chemotherapy.
  • [MeSH-major] Gestational Trophoblastic Disease / epidemiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide. Dactinomycin. Etoposide. Female. Humans. Hydatidiform Mole / drug therapy. Hydatidiform Mole / epidemiology. Hydatidiform Mole / etiology. Hydatidiform Mole / surgery. Incidence. Medical Audit. Medical Records. Methotrexate. Pregnancy. Retrospective Studies. South Africa / epidemiology. Vincristine

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12657130.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; EMA-CO protocol
  •  go-up   go-down


3. Herrgott I, Riemekasten G, Hunzelmann N, Sunderkötter C: Management of cutaneous vascular complications in systemic scleroderma: experience from the German network. Rheumatol Int; 2008 Aug;28(10):1023-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Even though SSc is a rare disease, timely and appropriate management of its vascular complications is mandatory for reducing the rate of major impairment.
  • We evaluated the diagnostic and therapeutic approach toward secondary RP and ulceration in SSc patients at 28 German clinical centers at the time of initiation of the German network for Systemic Scleroderma (DNSS).
  • Management of RP and ulcerations in SSc were heterogeneous at initiation of the network, reflecting a sometimes insufficient use of the diagnostic and therapeutic possibilities.
  • As such, (1) calcium channel blockers were the first line therapy in most centers; but often in insufficient dosages, and (2) only 21.2% of patients with acral ulceration had received prostacyclins when recruited into the network.
  • The sometimes insufficient care of vascular complications of SSc in Germany revealed the need for their standardized management, e.g. within a network for SSc and for consensus on a diagnostic or therapeutic algorithm.
  • [MeSH-major] Health Care Surveys. Raynaud Disease / drug therapy. Raynaud Disease / etiology. Scleroderma, Systemic / complications. Scleroderma, Systemic / drug therapy. Skin / blood supply
  • [MeSH-minor] Calcium Channel Blockers / therapeutic use. Germany. Humans. Professional Practice. Prostaglandins I / therapeutic use. Registries. Skin Ulcer / diagnosis. Skin Ulcer / drug therapy. Skin Ulcer / etiology. Surveys and Questionnaires. Vasodilator Agents / therapeutic use

  • Genetic Alliance. consumer health - Scleroderma.
  • Genetic Alliance. consumer health - Systemic Scleroderma.
  • MedlinePlus Health Information. consumer health - Raynaud's Disease.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1987 Nov;83(5):893-8 [3314499.001]
  • [Cites] Hautarzt. 2006 Oct;57(10):927-38; quiz 941 [16964476.001]
  • [Cites] Arch Intern Med. 1998 Mar 23;158(6):595-600 [9521223.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):2042-8 [11438158.001]
  • [Cites] Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii33-5 [16987831.001]
  • [Cites] Arthritis Rheum. 2001 Aug;44(8):1841-7 [11508437.001]
  • [Cites] Rheum Dis Clin North Am. 2003 May;29(2):293-313 [12841296.001]
  • [Cites] Z Rheumatol. 2006 Jul;65(4):285-9 [16804699.001]
  • [Cites] Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii49-51 [16987836.001]
  • [Cites] Arthritis Rheum. 2002 Sep;46(9):2410-20 [12355489.001]
  • [Cites] Ann Rheum Dis. 2007 Jun;66(6):754-63 [17234652.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD000953 [10796395.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD000954 [10796396.001]
  • [Cites] Ann Rheum Dis. 1995 Oct;54(10):853-5 [7492228.001]
  • [Cites] J Rheumatol. 1992 Sep;19(9):1407-14 [1279170.001]
  • [Cites] Int Angiol. 1994 Mar;13(1):10-4 [8077791.001]
  • [Cites] Rheum Dis Clin North Am. 1996 Nov;22(4):675-94 [8923590.001]
  • [Cites] Arthritis Rheum. 1999 Feb;42(2):306-10 [10025925.001]
  • [Cites] Br J Rheumatol. 1996 Nov;35(11):1127-31 [8948300.001]
  • [Cites] Angiology. 1986 Jun;37(6):433-9 [3729069.001]
  • [Cites] J Rheumatol. 2002 Jan;29(1):102-6 [11824945.001]
  • [Cites] Clin Exp Rheumatol. 1989 Sep-Oct;7 Suppl 3:S135-7 [2691149.001]
  • (PMID = 18320192.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Prostaglandins I; 0 / Vasodilator Agents
  •  go-up   go-down


Advertisement
4. Jen M, Murphy M, Grant-Kels JM: Childhood melanoma. Clin Dermatol; 2009 Nov-Dec;27(6):529-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood melanoma.
  • Pediatric melanoma is rare but increasing in incidence.
  • Because early diagnosis and treatment improves prognosis, clinicians need to include it as a possible diagnosis when evaluating a pigmented lesion in a pediatric patient.
  • Some risk factors for melanoma include xeroderma pigmentosum, giant congenital melanocytic nevi, dysplastic nevus syndrome, atypical nevi, many acquired melanocytic nevi, family history of melanoma, and immunosuppression.
  • Definitive treatment is with surgical excision.
  • Adjuvant therapies such as chemotherapy, immunotherapy, and radiation therapy can be used in advanced cases.
  • [MeSH-major] Melanoma / pathology. Neoplasm Invasiveness / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Age Factors. Biopsy, Needle. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Early Detection of Cancer. Female. Humans. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880040.001).
  • [ISSN] 1879-1131
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 117
  •  go-up   go-down


5. Ravot E, Comolli G, Lori F, Lisziewicz J: High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment. J Gene Med; 2002 Mar-Apr;4(2):161-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment.
  • BACKGROUND: Gene therapy has recently been advanced by the development of HIV-based vectors that are able to transduce some non-dividing cells.
  • In this study, a novel delivery strategy is developed to improve significantly the efficiency of HIV-based vectors in transducing non-dividing cells.
  • METHODS: Mature human monocyte-derived macrophages (14-21 days old) were transduced at a low multiplicity of infection (MOI) of HIV vectors carrying a reporter gene. dNSs were added to the medium during transduction (5 mM dNS) and immediately before post-transduction culture (2.5 mM dNS).
  • RESULTS: The addition of dNS to the medium significantly enhanced the efficiency of transduction of human macrophages by HIV-based vectors.
  • The percentage of cells expressing the transgene rose up to 50% in the presence of dNS, increasing the basal transduction levels up to 35-fold (average=10.8-fold).
  • Furthermore, treatment with dNTP precursors compensated for the wide inter-donor variability, allowing the highest enhancement effects in donors with the lowest basal transduction efficiencies.
  • CONCLUSIONS: This is the first demonstration that a single treatment of non-dividing target cells with exogenous dNS can enhance the efficiency of lentiviral-mediated transduction of cells, allowing for high efficiency gene transfer.
  • This simple approach might be transferred to a broader range of quiescent cell types that are scarcely susceptible to lentiviral-based gene delivery due to low dNTP levels.
  • [MeSH-minor] 3T3 Cells. Animals. Cell Division. Cell Line. Dose-Response Relationship, Drug. HIV / genetics. Humans. Macrophages / metabolism. Mice. Retroviridae / genetics. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Time Factors. Transduction, Genetic

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 11933217.001).
  • [ISSN] 1099-498X
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 533-67-5 / Deoxyribose
  •  go-up   go-down


6. Lo CP, Chen SY, Chou MC, Wang CY, Lee KW, Hsueh CJ, Chen CY, Huang KL, Huang GS: Diffusion-tensor MR imaging for evaluation of the efficacy of hyperbaric oxygen therapy in patients with delayed neuropsychiatric syndrome caused by carbon monoxide inhalation. Eur J Neurol; 2007 Jul;14(7):777-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-tensor MR imaging for evaluation of the efficacy of hyperbaric oxygen therapy in patients with delayed neuropsychiatric syndrome caused by carbon monoxide inhalation.
  • The purpose of this study is to assess the efficacy of hyperbaric oxygen therapy (HBOT) in patients with delayed neuropsychiatric syndrome (DNS) caused by carbon monoxide (CO) inhalation using diffusion tensor magnetic resonance (MR) imaging and neuropsychological test.
  • Conventional and diffusion tensor brain MR imaging exams were performed in six patients with DNS immediately before and 3 months after the HBOT to obtain fractional anisotropy (FA) values.
  • Diffusion tensor MR imaging can be a quantitative method for the assessment of the white matter change and monitor the treatment response in patients of CO-induced DNS with a good clinical correlation.
  • HBO may be an effective therapy for DNS.
  • [MeSH-major] Affective Symptoms / therapy. Carbon Monoxide Poisoning / therapy. Cognition Disorders / therapy. Demyelinating Diseases / pathology. Diffusion Magnetic Resonance Imaging / methods. Hyperbaric Oxygenation. Myelin Sheath / pathology
  • [MeSH-minor] Adult. Anisotropy. Depressive Disorder / complications. Depressive Disorder / psychology. Female. Follow-Up Studies. Humans. Lipid Peroxidation. Male. Middle Aged. Movement Disorders / etiology. Movement Disorders / pathology. Movement Disorders / therapy. Neuropsychological Tests. Suicide, Attempted. Time Factors

  • MedlinePlus Health Information. consumer health - Carbon Monoxide Poisoning.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594334.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Hunzelmann N, Riemekasten G: [Pulmonary arterial hypertension in collagen disease: experiences of the German Network for Systemic Scleroderma]. Dtsch Med Wochenschr; 2006 Dec 8;131(49 Suppl 9):S325-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary arterial hypertension in collagen disease: experiences of the German Network for Systemic Scleroderma].
  • The German Network for Systemic Scleroderma (Deutsches Netzwerk Für Systemische Sklerodermie [DNSS]) has as its aim to improve and standardize the diagnosis and treatment of this rare disease.
  • Aggressive immunosuppressive treatment--in the first instance with cyclophosphamide--should be given only if there is also progressive fibrosis.
  • Drugs that lower the level of PHT also have a favourable effect on other signs of scleroderma.
  • [MeSH-major] Connective Tissue Diseases / complications. Hypertension, Pulmonary / etiology. Immunosuppressive Agents / therapeutic use. Scleroderma, Systemic / complications
  • [MeSH-minor] Catheterization, Swan-Ganz. Echocardiography. Germany / epidemiology. Humans. Prognosis. Pulmonary Fibrosis / drug therapy. Pulmonary Fibrosis / etiology. Pulmonary Wedge Pressure. Societies, Medical / organization & administration


8. Shiose Y, Kuga H, Ohki H, Ikeda M, Yamashita F, Hashida M: Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates. Bioconjug Chem; 2009 Jan;20(1):60-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates.
  • The primary purpose of this study was to comprehensively delineate specificity of the peptide spacer sequence to tumor-expressed proteases for the design of macromolecular carrier-peptide spacer-drug conjugate system.
  • 225 conjugates of carboxymethyldextran polyalcohol (CM-Dex-PA) as water-soluble carrier and a dansyl derivative (N-(4-aminobutyl)-5-(dimethylamino)-1-naphthalenesulfonamide, DNS) as the model drug linked with different tetrapeptide spacers (Gly-Gly-P(2)-P(1), P(2), P(1): Ala, Asn, Gly, Cit, Gln, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) were combinatorially synthesized.
  • First, the drug release assay of all of the fluorogenic model conjugates was performed in murine Meth A solid tumor homogenates.
  • The drug release rate was higher with conjugates having hydrophobic amino acids at P(2).
  • It was also found that conjugates with Asn release the drug rapidly and, in contrast, those with Pro does not.
  • Second, we selected three peptide spacers (Gly-Gly-Phe-Gly, Gly-Gly-Ile-Gly, Gly-Gly-Pro-Leu), which release only DNS at different rates, and applied them to doxorubicin (DXR) conjugates.
  • These three DXR conjugates were used for investigating relationships with drug release, pharmacokinetics, and antitumor activity against Meth A bearing mice of these conjugates.
  • The release of DXR from the conjugates corresponded well with that of DNS conjugates in tumor homogenates.
  • Taken with the fact that the drug release rate in tumor homogenates was approximately 10-fold different between these two DXR conjugates, it is likely that cellular uptake of the conjugate would be rate-limiting, rather than the drug release process under the in vivo situation.
  • However, much weaker antitumor activity was observed with CM-Dex-PA-Gly-Gly-Pro-Leu-DXR, of which the drug release was extremely slow.
  • [MeSH-minor] Amino Acid Sequence. Animals. Antigens, Neoplasm. Drug Carriers / chemistry. Drug Carriers / pharmacokinetics. Histocompatibility Antigens. Mice. Neoplasms / drug therapy. Treatment Outcome

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19090781.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Drug Carriers; 0 / Histocompatibility Antigens; 0 / Peptides; 0 / Prodrugs; 0 / tumor-associated transplantation antigen; 80168379AG / Doxorubicin; 9044-05-7 / carboxymethyl dextran; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


9. Raza ML, Zeeshan M, Ahmad M, Shaheen F, Simjee SU: Anticonvulsant activity of DNS II fraction in the acute seizure models. J Ethnopharmacol; 2010 Apr 21;128(3):600-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticonvulsant activity of DNS II fraction in the acute seizure models.
  • Other species of Delphinium are reported as anticonvulsant and are traditionally used in the treatment of epilepsy.
  • DNS II acetone was chosen for further testing in the acute seizure models of epilepsy to study the antiepileptic potential in male mice.
  • MATERIALS AND METHODS: Different doses (60, 65 and 70mg/kg, i.p.) of DNS II acetone fraction of Delphinium nordhagenii was administered 30min prior the chemoconvulsant's injection in the male mice.
  • Moreover, four different doses of DNS II (60, 65, 70 and 100mg/kg, i.p.) were tested in the MES test.
  • RESULTS: The DNS II acetone fraction of Delphinium nordhagenii has exhibited the anticonvulsant actions by preventing the seizures against PTZ- and picrotoxin-induced seizure as well as 100% seizure protection in MES test.
  • [MeSH-major] Anticonvulsants / therapeutic use. Epilepsy / drug therapy. Epilepsy / prevention & control. Seizures / drug therapy. Seizures / prevention & control
  • [MeSH-minor] Acetone / therapeutic use. Animals. Delphinium / chemistry. Diazepam / therapeutic use. Male. Melanoma / drug therapy. Mice. Mice, Inbred Strains. Pakistan. Pentylenetetrazole / therapeutic use. Phenytoin / therapeutic use. Picrotoxin / therapeutic use. Ranunculaceae / chemistry. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Seizures.
  • Hazardous Substances Data Bank. PICROTOXIN .
  • Hazardous Substances Data Bank. DIAZEPAM .
  • Hazardous Substances Data Bank. PHENYTOIN .
  • Hazardous Substances Data Bank. ACETONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20138136.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anticonvulsants; 124-87-8 / Picrotoxin; 1364PS73AF / Acetone; 6158TKW0C5 / Phenytoin; Q3JTX2Q7TU / Diazepam; WM5Z385K7T / Pentylenetetrazole
  •  go-up   go-down


10. Chuang KH, Cheng CM, Roffler SR, Lu YL, Lin SR, Wang JY, Tzou WS, Su YC, Chen BM, Cheng TL: Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. Bioconjug Chem; 2006 May-Jun;17(3):707-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
  • Combination therapy can help overcome limitations in the treatment of heterogeneous tumors.
  • In the current study, we examined whether multiple therapeutic agents could be targeted to anti-dansyl single-chain antibodies (DNS scFv) that were anchored on the plasma membrane of cancer cells.
  • Functional DNS scFv could be stably expressed on CT-26 colon cancer cells both in vitro and in vivo.
  • Dansyl moieties were covalently attached to recombinant beta-glucuronidase (betaG) and interleukin 2 (IL-2) via a flexible poly(ethylene glycol) linker to form DNS-PEG-betaG and DNS-PEG-IL-2 conjugates.
  • The conjugates selectively bound CT-26 cells that expressed anti-DNS scFv (CT-26/DNS cells) but not CT-26 cells that expressed control scFv (CT-26/phOx cells).
  • DNS-PEG-betaG preferentially activated a glucuronide prodrug (BHAMG) of p-hydroxy aniline mustard at CT-26/DNS cells in culture and accumulated in subcutaneous CT-26/DNS tumors after intravenous administration.
  • Systemic administration of DNS-PEG-IL-2 or DNS-PEG-betaG and BHAMG significantly delayed the growth of CT-26/DNS but not control CT-26/phOx tumors.
  • Combination treatment with DNS-PEG-betaG and BHAMG followed by DNS-PEG-IL-2 therapy significantly suppressed the growth of CT-26/DNS tumors as compared to either single-agent regimen.
  • These results show that at least two DNS-modified therapeutic agents can be selectively delivered to DNS scFv receptors in vitro and in vivo, allowing combination therapy of DNS scFv-modified tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Glucuronidase / pharmacology. Haptens / immunology. Interleukin-2 / pharmacology. Neoplasms / drug therapy. Neoplasms / immunology. Prodrugs / metabolism
  • [MeSH-minor] Animals. Antibodies / immunology. Cell Line, Tumor. Drug Therapy, Combination. Mice. Mice, Inbred BALB C. Polyethylene Glycols / chemistry

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704208.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antineoplastic Agents; 0 / Haptens; 0 / Interleukin-2; 0 / Prodrugs; 30IQX730WE / Polyethylene Glycols; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


11. Steed ME, Vidaillac C, Rybak MJ: Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother; 2010 Dec;54(12):5187-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although infections with daptomycin-nonsusceptible (DNS) MRSA are infrequent, optimal therapy of these strains has not been determined.
  • We investigated the killing effects of novel antibiotic combinations with daptomycin (DAP) against two clinical DNS MRSA isolates (SA-684 and R6003) in a 72-h in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated endocardial vegetations (SEV).
  • The unique combination of DAP plus TMP/SMX was the most effective and rapidly bactericidal regimen against the two isolates tested and may provide a clinical option to treat DNS S. aureus infections.
  • [MeSH-major] Anti-Infective Agents / pharmacology. Daptomycin / pharmacology. Methicillin-Resistant Staphylococcus aureus / drug effects
  • [MeSH-minor] Acetamides / pharmacology. Cephalosporins / pharmacology. Drug Combinations. Endocarditis, Bacterial / microbiology. Linezolid. Microbial Sensitivity Tests. Nafcillin / pharmacology. Oxazolidinones / pharmacology. Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology

  • MedlinePlus Health Information. consumer health - MRSA.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. NAFCILLIN .
  • Hazardous Substances Data Bank. LINEZOLID .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Ther. 2000 Jan;22(1):66-75 [10688391.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Oct;53(10):4127-32 [19635961.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Feb;45(2):454-9 [11158740.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jun;45(6):1799-802 [11353628.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jun;45(6):1843-6 [11353635.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Aug;46(8):2606-12 [12121940.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Aug;47(8):2682-4 [12878541.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jan;48(1):63-8 [14693519.001]
  • [Cites] J Antimicrob Chemother. 1985 Jan;15 Suppl A:125-30 [3980323.001]
  • [Cites] Antimicrob Agents Chemother. 1987 Dec;31(12):1982-8 [3439805.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Dec;36(12):2709-14 [1336344.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72 [15561842.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jan;49(1):302-8 [15616309.001]
  • [Cites] Ann Pharmacother. 2005 Mar;39(3):427-32 [15701775.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jul;49(7):2735-45 [15980344.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):2137-45 [16723576.001]
  • [Cites] Int J Antimicrob Agents. 2006 Oct;28(4):280-7 [16963232.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Oct;50(10):3245-9 [17005801.001]
  • [Cites] Diagn Microbiol Infect Dis. 2007 Apr;57(4):459-65 [17240105.001]
  • [Cites] J Antimicrob Chemother. 2007 Aug;60(2):334-40 [17540670.001]
  • [Cites] Clin Infect Dis. 2007 Sep 1;45(5):601-8 [17682996.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8 [17620372.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jan;52(1):269-78 [17954690.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Mar;52(3):831-6 [17999971.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):433-7 [18214559.001]
  • [Cites] Diagn Microbiol Infect Dis. 2008 Jun;61(2):235-9 [18314293.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2223-5 [18378708.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2156-62 [18411321.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Sep;52(9):3061-7 [18591272.001]
  • [Cites] J Antimicrob Chemother. 2008 Dec;62(6):1305-10 [18801920.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Dec 1;178(11):1180-5 [18787216.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Jun;53(6):2636-7 [19289517.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Jun;53(6):2312-8 [19332678.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Sep;53(9):3981-4 [19564361.001]
  • [Cites] Diagn Microbiol Infect Dis. 2009 Oct;65(2):158-62 [19748426.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jul;44(7):1925-9 [10858356.001]
  • (PMID = 20921318.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / Anti-Infective Agents; 0 / Cephalosporins; 0 / Drug Combinations; 0 / Oxazolidinones; 4CNZ27M7RV / Nafcillin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 807PW4VQE3 / cefepime; ISQ9I6J12J / Linezolid; NWQ5N31VKK / Daptomycin
  • [Other-IDs] NLM/ PMC2981245
  •  go-up   go-down


12. Lipkowski AW, Misicka A, Kosson D, Kosson P, Lachwa-From M, Brodzik-Bienkowska A, Hruby VJ: Biological properties of a new fluorescent biphalin fragment analogue. Life Sci; 2002 Jan 11;70(8):893-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper presents data that replacement of the phenylalanine with a dansyl (X=DNS) groups gives an analogue (AA2016) that fully preserves the high affinity of the initial analogue for both mu and delta opioid receptors.
  • Because AA2016 contains a strong fluorescent group, it can be a very useful tool for prospective studies in vivo, including biological barrier permeability, tissue distribution, metabolism and receptor-ligand complex formation.
  • [MeSH-minor] Analgesia. Animals. Dansyl Compounds. Male. Pain / drug therapy. Pain / metabolism. Phenylalanine. Rats. Rats, Wistar. Receptors, Opioid, delta / metabolism. Receptors, Opioid, mu / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11853227.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA 06284
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics; 0 / Dansyl Compounds; 0 / Enkephalins; 0 / Fluorescent Dyes; 0 / Receptors, Opioid, delta; 0 / Receptors, Opioid, mu; 47E5O17Y3R / Phenylalanine; 83916-01-2 / biphalin
  •  go-up   go-down






Advertisement